Actively Recruiting
Study of Triapine and Temozolomide Combination Therapy for Recurrent Glioblastoma Evaluating Safety, Dosage, and Treatment Effects
Led by Northwestern University · Updated on 2026-09-09
22
Participants Needed
1
Research Sites
214 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, side effects, and best dose of triapine combined with temozolomide for patients with recurrent glioblastoma, a type of brain tumor that has returned after improvement. Triapine works by blocking an enzyme needed for DNA production, potentially slowing tumor growth, while temozolomide damages tumor cell DNA to stop growth. This Phase 1 trial aims to determine the recommended dose and assess treatment effects including progression and overall survival. Participants are assigned to one of three groups based on whether they plan to undergo surgery. Groups 1 and 2 receive oral temozolomide and triapine daily for five days every 28-day cycle, up to six cycles, without surgery. Group 3 receives triapine for five days before surgical tumor removal, then temozolomide and triapine as in the other groups. Treatment continues until disease progresses or unacceptable side effects occur. During the study, participants undergo MRI scans at screening and throughout treatment, along with blood sample collections. After completing treatment, they have a follow-up visit 30 days later and then every three months for up to two years. Researchers will monitor safety, tumor response, survival times, drug levels, quality of life, and tumor evolution through various assessments and questionnaires to better understand this combination therapy.
CONDITIONS
Brief Title
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Research Team
S
Study Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here